



**SENDERRA**  
Specialty Pharmacy  
3712 E. Plano Parkway, Ste. 200  
Plano, TX 75074  
*This prescription form is to be sent & received via fax*

**Adalimumab Biosimilar  
adalimumab-aacf  
Simlandi  
Yuflyma  
Yusimry  
Enrollment Form**  
  
**Physician Offices Call:  
855-460-7928**  
  
**Fax: 888-777-5645**

**Prescriber:**  
  
**Supervising Physician:**  
  
**Address:**  
  
**Phone:** **Fax:**  
  
**Contact:**

**NPI:**  
  
**NPI:**  
  
**Tax ID:**

**PATIENT INFORMATION**

Name:

☐ M
☐ F
☐ Trans M
☐ Trans F
☐ Other

DOB:
/
/
SS#:
-
-

Street:
City:
State:
ZIP:

Phone:
Alt. Phone:

☐ English
☐ Spanish
☐ Other:

Wt.:
Ht.:

**PRESCRIPTION**

Has the patient received a loading dose/starter kit?
☐ Yes Start Date:
/
/
☐ No
Ship to:
☐ Patient's Home
☐ Doctor's Office
☐ Other:

Drug	Directions & Quantity	Refills
<b>adalimumab-aacf</b> <input type="checkbox"/> Psoriasis/Uveitis Starter Package <input type="checkbox"/> Crohn's/UC Starter Package <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg/0.8 mL Pre-filled Syringe	<b>INITIAL/LOADING DOSES:</b> ***WEIGHT REQUIRED*** <input type="checkbox"/> <b>PSORIASIS/UEITIS:</b> Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every <b>other</b> week (Quantity: 4) <input type="checkbox"/> <b>CROHN'S/UC:</b> Inject 160 mg SQ on day 1, then 80 mg on day 15 (Quantity: 6) ***Intended for ped CD patients ≥ 40 kg (88 lbs)*** <b>MAINTENANCE DOSES:</b> <input type="checkbox"/> Inject 40 mg SQ every <b>other</b> week (Quantity: 2) <input type="checkbox"/> Inject 40 mg SQ weekly (Quantity: 4) <input type="checkbox"/> Inject 80 mg SQ every <b>other</b> week (Quantity: 4)	
<b>Simlandi®</b> <input type="checkbox"/> 40 mg/0.4 mL Autoinjector	<b>INITIAL/LOADING DOSES:</b> ***WEIGHT REQUIRED*** <input type="checkbox"/> <b>PSORIASIS/UEITIS:</b> Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every <b>other</b> week (Quantity: 4) <input type="checkbox"/> <b>CROHN'S/UC/HS:</b> Inject 160 mg SQ on day 1, then 80 mg on day 15 (Quantity: 6) ***Intended for ped CD patients ≥ 40 kg (88 lbs)*** <b>MAINTENANCE DOSES:</b> <input type="checkbox"/> Inject 40 mg SQ every <b>other</b> week (Quantity: 2) <input type="checkbox"/> Inject 40 mg SQ weekly (Quantity: 4) <input type="checkbox"/> Inject 80 mg SQ every <b>other</b> week (Quantity: 4)	
<b>Yuflyma®</b> <input type="checkbox"/> Crohn's/UC/HS Starter Package <input type="checkbox"/> 80 mg/0.8 mL Autoinjector <input type="checkbox"/> 40 mg/0.4 mL Autoinjector <input type="checkbox"/> 40 mg/0.4 mL Pre-filled Syringe <input type="checkbox"/> 20 mg/0.2 mL Pre-filled Syringe	<b>INITIAL/LOADING DOSES:</b> ***WEIGHT REQUIRED*** <input type="checkbox"/> <b>PSORIASIS/UEITIS:</b> Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every <b>other</b> week (Quantity: 4) <input type="checkbox"/> <b>CROHN'S/UC/HS:</b> Inject 160 mg SQ on day 1, then 80 mg on day 15 (Quantity: 6) ***Intended for ped CD patients ≥ 40 kg (88 lbs)*** <b>MAINTENANCE DOSES:</b> <input type="checkbox"/> Inject 40 mg SQ every <b>other</b> week (Quantity: 2) <input type="checkbox"/> Inject 40 mg SQ weekly (Quantity: 4) <input type="checkbox"/> Inject 80 mg SQ every <b>other</b> week (Quantity: QS 28 Days) <input type="checkbox"/> Inject 20 mg SQ every <b>other</b> week (Quantity: 2) ***Intended for JIA patients 15 kg (33 lbs) to <30 kg (66 lbs) OR Crohn's disease patients 17 kg (37 lbs) to less than 40 kg (88 lbs)***	
<b>Yusimry®</b> <input type="checkbox"/> 40 mg/0.8 mL Pen	<b>INITIAL/LOADING DOSES:</b> ***WEIGHT REQUIRED*** <input type="checkbox"/> <b>PSORIASIS/UEITIS:</b> Inject 80 mg SQ on day 1, 40 mg on day 8, then 40 mg every <b>other</b> week (Quantity: 4) <input type="checkbox"/> <b>CROHN'S/UC/HS:</b> Inject 160 mg SQ on day 1, then 80 mg on day 15 (Quantity: 6) ***Intended for ped CD patients ≥ 40 kg (88 lbs)*** <b>MAINTENANCE DOSES:</b> <input type="checkbox"/> Inject 40 mg SQ every <b>other</b> week (Quantity: 2) <input type="checkbox"/> Inject 40 mg SQ weekly (Quantity: 4) <input type="checkbox"/> Inject 80 mg SQ every <b>other</b> week (Quantity: 4)	

**MEDICAL INFORMATION**

\*\*\*PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY\*\*\*

PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:
<input type="checkbox"/> Methotrexate <input type="checkbox"/> Enbrel <input type="checkbox"/>	<input type="checkbox"/> ( ) <input type="checkbox"/> ( ) <input type="checkbox"/> ( )	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	   
<input type="checkbox"/> H20.9 Iridocyclitis (Uveitis), Unspecified <input type="checkbox"/> L40.0 Psoriasis Vulgaris (Plaque Psoriasis) <input type="checkbox"/> M05.9 Rheumatoid Arthritis with Rheumatoid Factor, unspecified <input type="checkbox"/> M08.09 Unspecified juvenile RA, multiple sites (pcJIA)	<input type="checkbox"/> K50.90 Crohn's disease unspecified, without complications <input type="checkbox"/> L40.50 Arthropathic Psoriasis, unspecified (Psoriatic Arthritis) <input type="checkbox"/> M06.09 Rheumatoid Arthritis without Rheumatoid Factor, multiple sites <input type="checkbox"/> M45.9 Ankylosing Spondylitis, unspecified	<input type="checkbox"/> K51.90 Ulcerative Colitis unspecified, without complications <input type="checkbox"/> L73.2 Hidradenitis suppurativa <input type="checkbox"/> M06.9 Rheumatoid Arthritis, unspecified <input type="checkbox"/> Other:	
<b>Date of Diagnosis:</b> / / <b>Allergies:</b>			
Active TB is ruled out: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: / /		Hep B ruled out/treated: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: / /	
<b>Additional Clinical Information:</b>			

**INJECTION TRAINING**

☐ Patient has received pen and injection training
☐ Physician's office to provide injection training
☐ Senderra to coordinate injection training

**PRESCRIBER SIGNATURE**

**To Prescriber:** By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.  
**Prescriber:**
**Date:**
/
/

**CONFIDENTIALITY NOTICE**

**IMPORTANT:** This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Adalimumab Biosimilar-adalimumab-aacf/Simlandi/Yuflyma/Yusimry (Rev.04/04/2025)